A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia
Tekijät: Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van t' Veer MB, Tjonnfjord GE, Itala-Remesg MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, Van Oers MHJ, Geisler CH, Niemann CU
Kustantaja: TAYLOR & FRANCIS LTD
Julkaisuvuosi: 2017
Journal: Leukemia and Lymphoma
Tietokannassa oleva lehden nimi: LEUKEMIA & LYMPHOMA
Lehden akronyymi: LEUKEMIA LYMPHOMA
Vuosikerta: 58
Numero: 10
Aloitussivu: 2356
Lopetussivu: 2362
Sivujen määrä: 7
ISSN: 1042-8194
DOI: https://doi.org/10.1080/10428194.2017.1285027
Tiivistelmä
CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.
CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.
Turun yliopiston Tutkimustietojärjestelmän portaali